Mantle Cell Lymphoma: Novel Scoring System May Aid in Determining Prognosis
Using data from 108 patients, researchers designed MIPI-P, a novel scoring system for determining MCL prognosis.
ASCO 2020
Understanding Patient Needs May Increase Treatment Rates in AML
Physicians noted that patients receiving best supportive care were more likely to be interested in low-intensity treatments if the risk for side effects was lower.
Promising Early Results for Use of an Oral THC/CBD Extract As Secondary Prophylaxis in the Setting of CINV
This phase 2 study used a crossover design in which study medication and placebo were administered to all patients in cycles A and B of chemotherapy, respectively.
Disconnect Between FDA Approval of Oncology Drugs and Publication of Results of Registration Trials
No systematic investigations have evaluated the publication timing of oncology drug registration trial results relative to the approval of these drugs by the FDA.
Are Adverse Events More Common After Radiotherapy With Immunotherapy?
Researchers aimed to determine whether the addition of radiotherapy was associated with a risk for adverse events among patients treated with ICIs.
GC027 Shows Promise as Therapy for Adult Relapsed, Refractory T-Cell ALL
All 5 patients had a complete response or complete response with incomplete hematologic recovery, and 4 of the 5 patients were minimal residual disease–negative.
Risk of Secondary AML May Be Increasing Among Patients With Refractory Anemia
Despite survival improvements in refractory anemia compared with other subtypes of MDS, patients may still have an increased risk for secondary AML.
A Majority of Anticancer Drug Approvals Are Based on Trials With Core Limitations, Say Researchers
Core limitations were defined as lack of randomization, lack of overall survival data, inappropriate use of crossover, and use of suboptimal control arms.
Patient Relapse Time After Auto-HCT in Chemosensitive DLBCL Does Not Appear to Influence PFS
The data reinforce the need for direct comparison of CAR-T and autologous transplantation.
Head-to-Head: Zanubrutinib vs Ibrutinib in Waldenström Macroglobulinemia
Zanubrutinib demonstrated statistically significant and clinically meaningful advantages in safety and tolerability in patients with WM compared with ibrutinib.
- Loading...
Loading...
Next post in ASCO 2020
Loading... 
Loading...